Julia Glade Bender, MD

About Me

I am a pediatric oncologist who specializes in caring for young people with solid tumors of the bone and soft tissues, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, germ cell tumors, and other rare tumors. As cliché as it might sound, I love talking to kids of all ages through young adulthood. With five kids of my own, I’ve had a lot of practice. It is both an honor and a privilege to guide patients and their families through what is likely to be the most difficult experience of their lives. There is no greater satisfaction than delivering a child back to the life they were meant to lead and allowing them to become the person they were destined to be.

I am also attracted to the emotional and intellectual challenges of diagnosing, understanding, and treating complex illnesses. To provide the best treatment available and to build the most effective team around a child, I strive to understand each person as an individual. How families communicate, how people cope, and what they need also come into play. With 80 percent of pediatric cancer patients surviving, the context of cancer care during developmental stages can have a profound impact. Kids still need to play like kids. Adolescents and young adults will struggle with issues of independence.

Likewise, there’s a lot about tumor biology that can be translated into better therapies for children. We need to understand what makes an individual tumor tick and shut it down. For many people, standard chemotherapy using existing anticancer drugs will continue to be the best approach. But for others, there’s great hope that newer technologies will result in better biologic and targeted therapies. These advances can take advantage of the differences between tumor cells and normal cells. At Memorial Sloan Kettering, every child’s tumor undergoes genetic sequencing. This testing allows us to quickly identify whether there are newer drugs that can be added to or can replace standard therapies.

My research occurs by the bedside and in the clinic, in the form of clinical trials. I feel strongly that children should have access to drugs in the earliest stages of testing, especially if the drug has been developed to target specific cancer drivers identified in their tumors. At MSK, we have broad expertise and the newest therapies available, including those that help or train the body’s immune system to recognize cancer. We try our best to learn from every patient and share that knowledge. Each patient is an individual. What is good for one may not be the best choice for another.

My overarching goal is to apply research and clinical experience to improve the care of all young people with cancer. I hope that in the future, we can use more-effective therapies with fewer side effects. With my incredible colleagues, I put my heart and mind to work each day for the kids for we are honored to care for. I aim to cure cancer one patient at a time, and I’m not going to stop until we get there.

  • Clinical Expertise: Pediatric Sarcomas; Neuroblastoma; Rare Tumors; Tumors Resistant to Prior Therapy; Early Phase Clinical Trials; Precision Oncology; Adolescents and Young Adults
  • Awards and Honors: Castle Connolly: New York Magazine Top Doctors (2014, 2016-2018)
  • Languages Spoken: English
  • Education: MD, University of Pennsylvania School of Medicine
  • Residencies: General Pediatrics – Mount Sinai Medical Center
  • Fellowships: Pediatric Hematology/Oncology – Memorial Sloan Kettering Cancer Center
  • Board Certifications: Pediatric Hematology-Oncology; Pediatrics

See My Colleagues

Publications

Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.

Oberg JA, Ruiz J, Ali‐Shaw T, Schlechtweg KA, Ricci A, Kung AL, Chung WK, Appelbaum PS, Glade Bender JL, Levine JM. Whole‐Genome and Whole‐Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations, JCO Precision Oncology. 2018 :2, 1-11.

Oberg JA*, Glade Bender JL*, Sulis ML*, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine. Genome Medicine. Dec 23, 2016; 8(1):133. DOI: 10.1186/s13073-016-0389-6. [PMID: 28007021] *Contributed equally

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print].

Tannenbaum-Dvir S, Glade-Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene 1 EML4-NTRK3 in an aggressive case of congenital fibrosarcoma. Cold Spring Harbor Molecular Case Studies. 2015: a000471.

Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children’s oncology group phase I consortium. Pediatr Blood Cancer. Pediatr Blood Cancer. 2015 Jan;62(1):45-51. [Epub 2014 Sep 24; PMID:25257751].

Glade Bender J, Lee A, Reid JM, Baruchel S, Roberts T, Voss S, Wu B, Ahern C, Ingle AM, Harris P, Weigel B, Blaney SM. A Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children with Refractory Solid Tumors including Soft Tissue Sarcoma: A Children’s Oncology Group Phase I Consortium Report. J Clin Oncol. 2013 Aug 20;31(24):3034-3043. [Epub 2013 Jul 15; PMID: 23857966].

Glade Bender J, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR.  A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2012 Sep 15;18(18):5081-9. [PMID: 22791883].

Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM,  Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405[PMID: 18202416].


Visit PubMed for a full listing of Julia Glade Bender’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more Arrow rightAn icon showing an arrow pointing to the right.

Insurance

Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.